HS-HCV

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameHS-HCV

Drug Alias Nameantiviral therapy (Heat Biologics)gp-96-Ig + unspecified viral antigen secreting live cell vaccine (Heat Biologics)endoplasmin modulator (Heat Biologics)HS-HCV

ClassificationCell and gene therapy > Cell therapyBiologics > Protein drugs > Recombinant protein > Fusion proteinVaccines > Application > Therapeutic vaccine +[4]

Mechanisms of ActionHeat Shock Protein 90 Beta Family Member 1 modulators

TargetsHeat Shock Protein 90 Beta Family Member 1

Therapy Area/IndicationsHepatitis C

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesScorpius Holdings Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesScorpius Holdings Inc

Active IndicationsN/A

Inactive IndicationsHepatitis C

Other Information

ATC CodeN/A